17,261 trials
Extensive Stage Small Cell Lung Cancer · Limited Stage Small Cell Lung Cancer · Recurrent Small Cell Lung Cancer
Primary: 6 Week Progression Free Survival — 43 percentage of participants
Chronic Hepatitis B
Primary: Percent Probability of Tolerability Failure — 18; 4; 11; 14 percent probability (KM estimate)
Spasmodic Torticollis
Primary: Maximum Rates of Extensor Digitorum Brevis (EDB) Muscle M-Wave Amplitude Reduction From Baseline — 9.02; 48.53; 70.95; 81.62 Percentage of Reduction
Cancer
Primary: Toxicity of Celecoxib With Concurrent Weekly Chemotherapy and Radiotherapy in the Treatment of Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and…
Tooth Erosion
Primary: Adjusted Mean Percent Net Erosion Resistance (NER) of Enamel Specimens Exposed to Test Dentifrice + Test MR Relative to: 1) Test Dentifrice+ Sterile Water Rinse 2)…
Multiple Myeloma
Primary: Phase 1: Participants With Dose-Limiting Toxicities (DLT) in Cycle 1 — 1; 1; 2; 4 participants
Lymphoma, Non-Hodgkin
Primary: Number of Participants (Par.) With Unconfirmed Response (Complete Response, Complete Response/Unconfirmed, or Partial Response), as Assessed by the Investigator — 30…
Carcinoma, Non-Small-Cell Lung
Primary: Maximum Tolerated Dose (MTD)of CP-751,871 in Combination With Paclitaxel and Carboplatin: Phase 1b — NA mg/kg
Glaucoma, Open-Angle
Primary: Percentage of Patients With a Visual Field Improvement in the Study Eye — 12.0; 9.5; 4.2 Percentage of Patients
Autism · Cognition Disorder
Primary: Change in Percentage of Time That Subjects With Autism Spend in REM Sleep. — 9.2 percentage of REM sleep
Upper Respiratory Tract Infection · Lower Respiratory Tract Infection
Primary: Circulating RI-001 Titer — 9.24; 4.85; 1.42 Fold Change
Retinitis Pigmentosa
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye — 48.5; 51.0; 52.7; 4.0 Number of Letters Read Correctly
Rhegmatogenous Macula-off Retinal Detachment
Primary: Percentage of Patients With at Least a 15-Letter Increase From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye — 6.7; 6.7; 0 Percentage of Patients
Metastatic Breast Cancer
Primary: Percentage of Participants With an Objective Response as Assessed Through Independent Radiologic Review — 32.7; 32.7 percentage of participants
Recurrent Non-small Cell Lung Cancer · Stage IIIA Non-small Cell Lung Cancer · Stage IIIB Non-small Cell Lung Cancer
Primary: Safety and Tolerability of IMC-A12 in Combination With Erlotinib Hydrochloride as Graded by Common Terminology Criteria for Adverse Event (CTCAE) Version 3.0 (DLTs…